The
The results beat
The drug developer posted revenue of
For the year, the company reported that its loss narrowed to
ImmunoGen expects full-year revenue in the range of
ImmunoGen shares have increased 5% since the beginning of the year. The stock has dropped nearly 2% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a
Automated Insights, source